Profile | GDS2987 / GI_22027645-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 7.4 | 27 |
GSM215244 | HMVEC_vehicle_rep2 | 50.5 | 69 |
GSM215253 | HMVEC_vehicle_rep3 | 17.6 | 49 |
GSM215254 | HMVEC_atorvastatin_rep1 | 11.7 | 31 |
GSM215282 | HMVEC_atorvastatin_rep3 | 33 | 58 |
GSM215344 | HMVEC_atorvastatin_rep2 | 26.7 | 53 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | 0.8 | 1 |
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 23.1 | 43 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 40.2 | 54 |
GSM215294 | HMVEC_SLx2119_rep1 | 19.7 | 55 |
GSM215295 | HMVEC_SLx2119_rep2 | 35.2 | 56 |
GSM215296 | HMVEC_SLx2119_rep3 | 23.8 | 38 |
GSM215297 | PASMC_vehicle_rep1 | 21 | 31 |
GSM215298 | PASMC_vehicle_rep2 | 1.5 | 2 |
GSM215310 | PASMC_vehicle_rep3 | ||
GSM215311 | PASMC_atorvastatin_rep1 | 62.1 | 68 |
GSM215312 | PASMC_atorvastatin_rep2 | 27.1 | 40 |
GSM215313 | PASMC_atorvastatin_rep3 | 21.9 | 32 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 24.3 | 39 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 37.4 | 57 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 40.8 | 56 |
GSM215327 | PASMC_SLx2119_rep1 | 6 | 11 |
GSM215328 | PASMC_SLx2119_rep2 | 18.6 | 33 |
GSM215329 | PASMC_SLx2119_rep3 | 50 | 64 |
GSM215330 | Fibroblasts_vehicle_rep1 | 18 | 39 |
GSM215331 | Fibroblasts_vehicle_rep2 | 21.8 | 50 |
GSM215332 | Fibroblasts_vehicle_rep3 | 16.7 | 47 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | ||
GSM215334 | Fibroblasts_atorvastatin_rep2 | 11.2 | 31 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 17.1 | 39 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 9 | 29 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 5.9 | 19 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 16.6 | 43 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 23.1 | 54 |
GSM215340 | Fibroblasts_SLx2119_rep2 | ||
GSM215341 | Fibroblasts_SLx2119_rep3 |